Answers are grounded in this paper and cite their sources.
We have developed a novel approach in cancer immunotherapy, the personalized peptide vaccination (PPV), in which human leukocyte antigen (HLA)-matched peptides are selected on the basis of preexisting host immunity before vaccination. Recently, we demonstrated the feasibility of PPV in previously treated patients with advanced colorectal cancer, thus warranting further clinical development of this approach.
No takes yet. Share an insight, caveat, or question.
Sasada et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: